New mRNA vaccines to improve T-cell therapies for solid tumors
Official title: Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
Funded at University of California Los Angeles · NIH-10982192 · Data updated 2026-11-12
This study is working on new mRNA vaccines that could help boost treatments for pancreatic cancer by making the immune system's T-cells better at fighting the cancer, and it's aimed at improving outcomes for patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $628,499 |
| NIH project number | 1R01CA283736-01A1 |
| Project ID | NIH-10982192 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
✕Less likely to help
Patients with cancers other than pancreatic ductal adenocarcinoma may not benefit from this specific research.
What this research studies
This research focuses on developing innovative mRNA vaccines that enhance the effectiveness of T-cell transfer therapies specifically for pancreatic cancer. By utilizing a modified mRNA technology that has shown success in COVID-19 vaccines, the project aims to create vaccines that can better stimulate the immune system's CD8+ T cells to target cancer cells. The research will involve mechanistic studies to optimize the vaccine's design and evaluate its performance in advanced animal models of pancreatic ductal adenocarcinoma. The ultimate goal is to improve treatment outcomes for patients with this challenging cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promising results using mRNA technology in cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Radu, Caius Gabriel — University of California Los Angeles
- Study coordinator: Radu, Caius Gabriel
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.